- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06391736
Utvärdering av säkerheten och effekten av sent debuterande genterapiläkemedlet för Pompes sjukdom
En multicentrerad, enkelarm, öppen märkt, studie för att utvärdera säkerheten, tolerabiliteten och effektiviteten hos en adenoassocierad virusvektor som uttrycker den humana syra alfa-glukosidas (GAA) transgen intravenös injektion hos patienter med sent debuterande Pompes sjukdom
This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with late-onset Pompe disease (LOPD) who are ≥ 6 years old will be studied.
Studieöversikt
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: GeneCradle, Inc China
- Telefonnummer: 86-13501380583
- E-post: ind@bj-genecradle.com
Studieorter
-
-
-
Beijing, Kina, 100853
- Rekrytering
- Chinese PLA General Hospital
-
Huvudutredare:
- Guang Yang
-
Kontakt:
- Xinting Liu
- Telefonnummer: 16601558283
- E-post: lxting0531@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 6 years, males or females;
- Patient has a diagnosis of LOPD;
- Patient has upright FVC ≥ 30% of predicted normal value;
- A 6MWT ≥ 40 meters, assistive device allowed;
- The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.
Exclusion Criteria:
- Patient who has any history or concurrent clinical organic disease, including cardiovascular and liver diseases, respiratory system, nervous system disease, or any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
- Patient who requires invasive mechanical ventilation, or rely on noninvasive non-non-invasive assisted ventilation when sitting upright;
- Patient who is positive for human immunodeficiency (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody;
- Patient with a history of glucocorticoid allergy;
- Patient who has a contraindication to study drug or to corticosteroids, or has demonstrated hypersensitivity to any of the components of the study drug;
- Patient who has AAV9 neutralizing antibody titer ≥ 1:100;
- Patient who has participated in a previous gene therapy research trial;
- Pregnant or lactating female participants;
- Patients who have fertility plans within 6 months from screening to the end of the study and are unwilling to take effective physical contraceptive measures (such as a condom, intrauterine device, contraceptive ring, ligation, abstinence, etc.) for contraception (including the subject's partner);
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Low dosage group
Single intravenous administration of GC301 at a dose of 3.0 x 10^13 vector genomes per kilogram body weight |
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene |
|
Experimentell: High dosage group
Single intravenous administration of GC301 at a dose of 6.0 x 10^13 vector genomes per kilogram body weight |
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Dosbegränsande toxicitetsfrekvens (DLT) baserat på protokollspecifika biverkningar (fas 1)
Tidsram: inom 30 dagar efter behandlingen
|
inom 30 dagar efter behandlingen
|
|
|
Number of Participants With Adverse Events
Tidsram: 52 weeks
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability |
52 weeks
|
|
Percent Predicted Upright Forced Vital Capacity (FVC)(Phase 2)
Tidsram: 52 weeks
|
Change from baseline in percentage of predicted FVC measured by pulmonary function testing |
52 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Förekomst av immunsvar mot AAV-kapsid och GAA-transgen
Tidsram: 52 veckor
|
52 veckor
|
|
|
6-Minute Walk Test
Tidsram: 52 weeks
|
Change from baseline in the distance walked in the 6 minute walk test (6MWT), which is a standardized assessment of how far an individual can walk on a hard, flat surface in a period of 6 minutes |
52 weeks
|
|
Maximum Inspiratory Pressure (MIP)
Tidsram: 52 weeks
|
Change from baseline in MIP measured by pulmonary function testing |
52 weeks
|
|
Maximum Expiratory Pressure (MEP)
Tidsram: 52 weeks
|
Change from baseline in MEP measured by pulmonary function testing |
52 weeks
|
|
Muscle Status Testing - Quick Motor Function Test (QMFT) Measure
Tidsram: 52 weeks
|
Measurement of functional motor abilities using the Quick Motor Function Test (QMFT) will be performed and the results compared with baseline. |
52 weeks
|
|
Quality of life evaluation: 12-item short form health survey (SF-12) for LOPD participants
Tidsram: 52 weeks
|
SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline. SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition. These eight domains were further summarized into 2 summary scores, physical component summary (PCS) and mental component summary (MCS). The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life. |
52 weeks
|
|
Time needed for non-invasive ventilatory support
Tidsram: 52 weeks
|
Change from baseline in time duration that needed for non-invasive ventilatory support |
52 weeks
|
|
The viral load of adeno-associated virus (AAV) vector
Tidsram: 52 weeks
|
To assess the change of AAV vector copy numbers within 52 weeks after administration. |
52 weeks
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
GAA enzymatic activity
Tidsram: 52 weeks
|
Change from baseline in GAA enzymatic activity in muscle biopsies |
52 weeks
|
|
GAA enzymatic activity
Tidsram: 52 weeks
|
Change from baseline in GAA enzymatic activity in blood |
52 weeks
|
|
Glycogen content in muscle
Tidsram: 52 weeks
|
Change from baseline in glycogen content in muscle biopsies |
52 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Guang Yang, Chinese PLA General Hospital
- Huvudutredare: Guang Yang, Chinese PLA General Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Metabolism, medfödda fel
- Genetiska sjukdomar, medfödda
- Metaboliska sjukdomar
- Kolhydratmetabolism, medfödda fel
- Lysosomala lagringssjukdomar
- Hjärnsjukdomar, metabola, medfödda
- Hjärnsjukdomar, metaboliska
- Lysosomala lagringssjukdomar, nervsystemet
- Glykogenlagringssjukdom
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Närings- och metabola sjukdomar
- Glykogenlagringssjukdom typ II
Andra studie-ID-nummer
- JLJY-GC301-LOPD-001
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .